WO2008033395A3 - Melanocortin and transferrin fusion proteins - Google Patents
Melanocortin and transferrin fusion proteins Download PDFInfo
- Publication number
- WO2008033395A3 WO2008033395A3 PCT/US2007/019809 US2007019809W WO2008033395A3 WO 2008033395 A3 WO2008033395 A3 WO 2008033395A3 US 2007019809 W US2007019809 W US 2007019809W WO 2008033395 A3 WO2008033395 A3 WO 2008033395A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- melanocortin
- transferrin
- moiety
- fusion proteins
- transferrin fusion
- Prior art date
Links
- 102000004338 Transferrin Human genes 0.000 title abstract 4
- 108090000901 Transferrin Proteins 0.000 title abstract 4
- 102000037865 fusion proteins Human genes 0.000 title abstract 4
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 239000012581 transferrin Substances 0.000 title abstract 4
- 108010008364 Melanocortins Proteins 0.000 title abstract 2
- 239000002865 melanocortin Substances 0.000 title 1
- 239000000336 melanocortin receptor agonist Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108010011459 Exenatide Proteins 0.000 abstract 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
- 229940117029 Melanocortin receptor agonist Drugs 0.000 abstract 1
- 102000007238 Transferrin Receptors Human genes 0.000 abstract 1
- 108010033576 Transferrin Receptors Proteins 0.000 abstract 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960001519 exenatide Drugs 0.000 abstract 1
- 230000013595 glycosylation Effects 0.000 abstract 1
- 238000006206 glycosylation reaction Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70582—CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention discloses fusion proteins comprising a transferrin moiety and a melanocortin or melanocortin receptor agonist moiety. In one embodiment of the invention, the transferrin moiety is modified to exhibit reduced or no glycosylation. In another embodiment, the transferrin moiety is modified to exhibit reduced or no binding to a transferrin receptor. The fusion protein of the invention can optionally comprise a linker peptide and/or a second therapeutic peptide such as GLP-1 or exendin-4. Also disclosed are methods of treating or preventing a disease or condition in a subject by administering a fusion protein of the invention.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84434806P | 2006-09-14 | 2006-09-14 | |
| US60/844,348 | 2006-09-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2008033395A2 WO2008033395A2 (en) | 2008-03-20 |
| WO2008033395A3 true WO2008033395A3 (en) | 2008-05-15 |
Family
ID=39125184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2007/019809 WO2008033395A2 (en) | 2006-09-14 | 2007-09-11 | Melanocortin and transferrin fusion proteins |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2008033395A2 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2259794A1 (en) * | 2008-02-22 | 2010-12-15 | Clinuvel Pharmaceuticals Limited | Method for treatment of photosensitivity and phototoxicity |
| WO2009147180A2 (en) * | 2008-06-05 | 2009-12-10 | Basf Se | Microbicidal peptides of trichoderma reesei |
| WO2011046983A2 (en) | 2009-10-12 | 2011-04-21 | Smith Holdings, Llc | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
| EP3208282A1 (en) | 2010-11-30 | 2017-08-23 | F. Hoffmann-La Roche AG | Low affinity anti transferrin receptor and their use to transfer therapeutic scfv across the blood brain barrier |
| US10232018B2 (en) | 2013-03-14 | 2019-03-19 | Mallinckrodt Ard Ip Limited | ACTH for treatment of acute respiratory distress syndrome |
| WO2015162486A1 (en) * | 2014-04-22 | 2015-10-29 | Txp Pharma Gmbh | Linear gamma msh with c- and / or n-terminal extensions of lysine and / or glutamic acid residues |
| WO2016069889A1 (en) * | 2014-10-31 | 2016-05-06 | Resolve Therapeutics, Llc | Therapeutic nuclease-transferrin fusions and methods |
| US10899796B2 (en) | 2015-11-09 | 2021-01-26 | Tufts Medical Center | Compounds and methods for treating pain |
| WO2018069442A1 (en) | 2016-10-12 | 2018-04-19 | University Of Copenhagen | Peptide dual agonists of gipr and glp2r |
| CN107573414B (en) * | 2017-08-14 | 2020-08-07 | 李翀 | Human bladder cancer marker AG-CD71, antibody ABC71 and application thereof |
| EP3810186B1 (en) | 2018-06-21 | 2022-09-28 | Novo Nordisk A/S | Novel compounds for treatment of obesity |
| TWI861780B (en) * | 2022-03-28 | 2024-11-11 | 南韓商Ｌｇ化學股份有限公司 | Combination therapy for preventing or treating obesity |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004020588A2 (en) * | 2002-08-30 | 2004-03-11 | Biorexis Pharmaceutical Corporation | Transferrin fusion protein libraries |
| WO2004019872A2 (en) * | 2002-08-30 | 2004-03-11 | Biorexis Pharmaceutical Corporation | Oral delivery of modified transferrin fusion proteins |
| WO2006017688A2 (en) * | 2004-08-03 | 2006-02-16 | Biorexis Pharmaceutical Corporation | Combination therapy using transferrin fusion proteins comprising glp-1 |
-
2007
- 2007-09-11 WO PCT/US2007/019809 patent/WO2008033395A2/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004020588A2 (en) * | 2002-08-30 | 2004-03-11 | Biorexis Pharmaceutical Corporation | Transferrin fusion protein libraries |
| WO2004019872A2 (en) * | 2002-08-30 | 2004-03-11 | Biorexis Pharmaceutical Corporation | Oral delivery of modified transferrin fusion proteins |
| WO2006017688A2 (en) * | 2004-08-03 | 2006-02-16 | Biorexis Pharmaceutical Corporation | Combination therapy using transferrin fusion proteins comprising glp-1 |
Non-Patent Citations (4)
| Title |
|---|
| DATABASE Geneseq [online] 27 January 2005 (2005-01-27), "Human transferrin protein.", XP002471765, retrieved from EBI accession no. GSP:ADU17611 Database accession no. ADU17611 * |
| MATSUBARA MUNEAKI ET AL: "Glucagon-like-peptide-1 fused to transferrin: A novel approach to myocardial reperfusion injury", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 49, no. 9, Suppl. A, March 2007 (2007-03-01), & 56TH ANNUAL SCIENTIFIC SESSION OF THE AMERICAN-COLLEGE-OF-CARDIOLOGY; NEW ORLEANS, LA, USA; MARCH 24 -27, 2007, pages 236A, XP009096973, ISSN: 0735-1097 * |
| MUNEAKI MATSUBARA, EARL ALBONE, JOSEPH H. GORMAN AND ROBERT C. GORMAN: "?-Melanocyte Stimulating Hormone Fused to Transferrin: A Novel Adjunct to Reperfusion Therapy for Acute MI", CARDIOVASCULAR PHYSIOLOGY, 1 August 2007 (2007-08-01), pages S92, XP002471736 * |
| RAFFIN-SANSON M L ET AL: "Proopiomelanocortin, a polypeptide precursor with multiple functions: From physiology to pathological conditions.", EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 149, no. 2, August 2003 (2003-08-01), pages 79 - 90, XP002471746, ISSN: 0804-4643 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008033395A2 (en) | 2008-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008033395A3 (en) | Melanocortin and transferrin fusion proteins | |
| WO2006024275A3 (en) | Glp-1 and exendin related invention | |
| WO2008036341A3 (en) | Compositions and methods relating to glucagon receptor antibodies | |
| GEP20146112B (en) | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and usage thereof | |
| WO2008143954A3 (en) | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto | |
| WO2009133137A3 (en) | Pegylated recombinant human growth hormone compounds | |
| WO2008066752A8 (en) | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir | |
| WO2007028394A3 (en) | Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort | |
| NZ585131A (en) | Use melanocortins to treat insulin sensitivity | |
| WO2007130455A3 (en) | Compositions and methods for treatment of non-hodgkins lymphoma | |
| WO2007070671A3 (en) | Therapeutic methods for inhibiting tumor growth with dll4 antagonists | |
| RU2014122609A (en) | ANTIBODY MODIFIED CONSTANT AREA | |
| WO2006087637A3 (en) | Anti her2/neu antibody | |
| MX2009007290A (en) | Glucagon-like protein-1 receptor (glp-1r) agonist compounds. | |
| MX2009002999A (en) | Protease resistant insulin analogues. | |
| WO2006017688A3 (en) | Combination therapy using transferrin fusion proteins comprising glp-1 | |
| NZ591130A (en) | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof | |
| WO2007091250A8 (en) | Enzyme replacement therapy for treating lysosomal storage diseases | |
| WO2009147248A3 (en) | Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases | |
| WO2007064727A3 (en) | Penetrabodies: receptor-mediated targeted delivery of functionally-active human antibody fragments into cytosol for the treatment of chronic infections and diseases | |
| WO2007067596A3 (en) | Methods and compositions for needleless delivery of antibodies | |
| WO2009025867A3 (en) | Compositions of humanized notch fusion proteins and methods of treatment | |
| EP1945240A4 (en) | Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof | |
| WO2008113515A3 (en) | huTNFR1 SELECTIVE ANTAGONISTS | |
| WO2007019865A3 (en) | Therapy with cd4 binding peptides and radiation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07838084 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07838084 Country of ref document: EP Kind code of ref document: A2 |